The ability to identify-early in the course of therapy-patients that are not responding to a particular neoadjuvant regimen would provide the opportunity to switch to a potentially more efficacious treatment and transform current practice. Unfortunately, existing methods of determining early response are inadequate. The vision for this program is to develop tumor-forecasting methods for predicting response in individual breast cancer patients after a single cycle of neoadjuvant therapy. We propose to combine time-resolved drug- response cell scale data with physiological and tissue scale imaging data in order to initialize and constrain a multi-scale angiogenesis-cell proliferation model designed to predict both size and spatial characteristics of breast tumors at the completion of therapy. To achieve this goal, we will pursue the following specific aims: 1. (Pre-clinical validation) In the BT-474 HER2+ human breast cancer cell line, we will obtain: 1a. (cell scale) in vitro data quantifying rates of entry of proliferating cells into quiescence and apoptosis; 1b. (physiologica scale) in vivo MRI and PET measurements of cellularity, vascularity, and metabolism; 1c. (tissue scale) in vivo MR elastography measurements to quantify the tumor mechanical properties; 1d. (all scales) in situ data from fixed tumor tissue to corroborate cell and imaging-based metrics. These data will be integrated into the multi-scale model to predict tumor response after one cycle of the targeted anti-HER2 agents trastuzumab and lapatinib. 2. (Clinical application) In HER2+ patients receiving neoadjuvant trastuzumab and lapatinib, we will obtain: 2a. (physiological scale) in vivo MRI and PET measurements of cellularity, vascularity, and metabolism; 2b. (tissue scale) in vivo MR elastography measurements to quantify tumor mechanical properties. Guided by the results from Aim 1, these data will be integrated into the multi-scale model and make predictions on breast tumor response outcomes after a single cycle of trastuzumab and/or lapatinib. If successful, our approach would be the foundation for high-impact, large-scale application in clinical settings.
We hypothesize that patient specific imaging data combined with an estimate of the effect of the neoadjuvant regimen on tumor cell phenotype, will enable a multi-scale model to accurately predict the response of breast tumors after a single cycle of therapy on an individual basis. Our goal is to provide the breast cancer community with a rigorous, practical method of predicting therapeutic response that is appropriate for incorporation into clinical trials and, ultimately, clinical practice.
|Yankeelov, Thomas E; Miga, Michael I (2016) Introduction to the Special Section on Clinical Applications of Multi-Scale Modeling. Ann Biomed Eng 44:2589-90|
|Sorace, Anna G; Quarles, C Chad; Whisenant, Jennifer G et al. (2016) Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results. Breast Cancer Res Treat 155:273-84|
|Yankeelov, Thomas E; An, Gary; Saut, Oliver et al. (2016) Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success. Ann Biomed Eng 44:2626-41|
|Harris, Leonard A; Frick, Peter L; Garbett, Shawn P et al. (2016) An unbiased metric of antiproliferative drug effect in vitro. Nat Methods 13:497-500|
|Sorace, Anna G; Syed, Anum K; Barnes, Stephanie L et al. (2016) Quantitative [(18)F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer. Mol Imaging Biol :|
|Abramson, Richard G; Arlinghaus, Lori R; Dula, Adrienne N et al. (2016) MR Imaging Biomarkers in Oncology Clinical Trials. Magn Reson Imaging Clin N Am 24:11-29|
|Conley, Rebekah H; Meszoely, Ingrid M; Weis, Jared A et al. (2015) Realization of a biomechanical model-assisted image guidance system for breast cancer surgery using supine MRI. Int J Comput Assist Radiol Surg 10:1985-96|
|Abramson, Richard G; Lambert, Katrina F; Jones-Jackson, Laurie B et al. (2015) Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer. Acad Radiol 22:853-9|
|Yankeelov, Thomas E; Quaranta, Vito; Evans, Katherine J et al. (2015) Toward a science of tumor forecasting for clinical oncology. Cancer Res 75:918-23|
|Barnes, Stephanie L; Sorace, Anna G; Loveless, Mary E et al. (2015) Correlation of tumor characteristics derived from DCE-MRI and DW-MRI with histology in murine models of breast cancer. NMR Biomed 28:1345-56|
Showing the most recent 10 out of 24 publications